US2003064940A1PendingUtilityA1
Kit for treating acne vulgaris using avermectin compound
Priority: Oct 2, 2001Filed: Jun 3, 2002Published: Apr 3, 2003
Est. expiryOct 2, 2021(expired)· nominal 20-yr term from priority
Inventors:L. Dean Parks
A61K 31/704A61Q 19/10A61K 8/498
48
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A kit for treating acne vulgaris are disclosed. The treatment includes topical application of a dermatological composition containing an avermectin compound to the affected areas of a patient alone, or in conjunction with other conventional methods of treating acne vulgaris. The dermatological composition of the kit contains an avermectin compound in a pharmaceutically acceptable carrier, including water, glycols, alcohols, lotions, creams, gels, emulsions, sprays, soaps, body washes, facial cleansers, and facial masks.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A kit for treating acne vulgaris comprising:
(a) a dermatological composition in a container, said dermatological composition comprising therapeutically effective amount of avermectin compound and a pharmaceutically acceptable carrier, and (b) instructions on, or associated with, said container regarding how to use said dermatological composition for treating acne vulgaris.
2 . The kit of claim 1 , wherein said avermectin compound comprises:
avermectins, avermectin derivatives, ivermectin, or ivermectin derivatives.
3 . The kit of claim 2 in said carrier comprises:
water, glycols, alcohols, lotions, creams, gels, emulsions, sprays, soaps, body washes, facial cleanser, and facial masks.
4 . The kit as recited in claim 1 , further comprising:
a therapeutically effective amount of at least one other anti-acne medication.
5 . The kit as recited in claim 4 , in which said at least one other anti-acne medication comprises benzoyl peroxide, sulfur, resorcinol, salicyclic acid, opioid, tretinoin, antibiotics, and isotretinoin.
6 . The kit as recited in claim 2 , in which said avermectin compound is in a dermatological composition comprising said avermectin compound in a concentration greater than about 0.05%, and a pharmaceutically acceptable carrier.Join the waitlist — get patent alerts
Track US2003064940A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.